Research Triangle Park, N.C.-based Viamet raised $4 million in a first round of funding. The round was co-led by Hatteras Venture Partners and Intersouth Partners.
Viamet is developing drugs that target metalloenzymes — a diverse group of catalyst molecules that include metal atoms — in infectious disease, inflammation and cancer. The company was founded in 2005.
Trackback URL
